ros production

Elamipretide (MTP-131) is a mitochondria-targeted antioxidant tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that reduces toxic reactive oxygen species (ROS) production and stabilizes cardiolipin, with blood-brain-barrier permeability. It is a potential therapeutic agent in the rare disease of Barnes syndrome.

Dynamin-related protein 1 (Drp1) inhibitor, inhibits Drp1 GTPase activity. Displays no effect on dynamin 1 or other mitochondrial dynamics-related proteins. Inhibits mitochondrial fission, dysfunction and reactive oxygen species (ROS) production in vitro.

Chemerin-9 (149-157) TFA is a potent CMKLR1 (chemokine-like receptor 1) agonist with anti-inflammatory properties. It activates phosphorylation of Akt and ERK and induces ROS production, beneficially modulating immune responses, adipocyte differentiation, and glucose metabolism. Additionally, it has been shown to alleviate Aβ 1-42-induced memory impairment, highlighting its therapeutic potential [1] [2] [3] [4].

HNGF6A TFA, a humanin analogue, enhances glucose-stimulated insulin secretion and glucose metabolism, offering potential for diabetes research. It also inhibits ROS (Reactive Oxygen Species) production under oxidative stress and may prevent endothelial dysfunction and atherosclerosis in vivo [1] [2].